

CURRICULUM VITAE

1.1 PERSONAL

Name: **Allan Joseph McLEAN**
Date of birth: 15th February, 1945.
Place of birth Oatlands, Tasmania, Australia.
Nationality: Australian
Marital status: Married with 3 adult sons.

1.2 EDUCATION & ACADEMIC AWARDS

Oatlands Primary School 1952-1956, award of a Tasmanian Country Bursary 1956-1959
Hobart State High School 1957-1961. Tasmanian Senior Bursary & Gowrie Trust Fund Scholarship 1960-61.
Dux of School 1960.
University of Tasmania Entrance Scholarship (1961) and Commonwealth Scholarship, 1962-1968
B Med Sci, Monash University, Melbourne, 1965, Supervisors-Prof ME Holman (Monash), Prof EE Daniel (McMaster Uni, Canada)
Theses: "The pharmacology of an isolated neuro-muscular preparation of sheep mesenteric veins."
"An Electrophysiological Study of the 'd' Response in Cat Spinal Cord (with Chapman, JB)"
MBBS (Hons I), Monash University, 1968
1970-1972 National Health & Medical Research Council Medical Postgraduate Fellowship
MRACP, 1974 (Membership, Royal Australasian College of Physicians)
Ph D, Monash University, 1976:
Thesis: "The actions of endotoxins in guinea pigs". Prof ME Holman (Monash), Prof G Feigen (Stanford Uni, California)
1977-1978 NHMRC Overseas Clinical Sciences Scholar (Clinical Pharmacology & Clinical Toxicology),
FRACP, 1977 (Fellowship, Royal Australasian College of Physicians)
Grad Cert Management (Technology Mgt), Deakin University/APESMA, 1997
Grad Dip Management (Technology Mgt), Deakin University/APESMA, 1998
Grad Cert Management, Monash Mt Eliza Executive MBA programme, 1998
Assoc Fellow Aust College Health Service Executives, 1998
Grad Dip Management, Monash Mt Eliza Executive MBA programme, 1999
MBA (Executive), Monash Mt Eliza Business School, 2004
Minor Thesis: "A strategic management plan for transformational change in the delivery of Geriatric medical services within the Australian Capital Territory and surrounding rural New South Wales Health Regions"

1.3 PRINCIPAL APPOINTMENTS (CURRENT & RECENT- 5 years)

2007- Mercy-Notre Dame Chair in Medicine, University of Notre Dame (Australia) School of Medicine (Sydney)
Associate Dean, UND School of Medicine (Sydney) and Clinical Dean, Victorian Clinical School,

Director of Clinical Services (Medical), Mercy Werribee Hospital and Mercy Health and Aged Care

- 2004 -2007 Director of Acute Geriatric Medicine, Royal Melbourne Hospital (until Jan 2007)
- 2001 -2006 Professor / Director, National Ageing Research Institute
- 2001- 2007 Senior Staff Specialist in Geriatric Medicine, Melbourne Health
- 2001 -2007 Professorial Fellow and Professor in Medicine, Department of Medicine, University of Melbourne
- 2001-2007 Member, Committee of Deans and Sub-Deans, University of Melbourne Faculty of Medicine, Nursing and Health Sciences
- 2001 -2004 Professor of Gerontology, Faculty of Health Sciences, University of Canberra
- 2001 - 2004 Director of Aged Care Services, Melbourne Health
- 2001 - 2004 Director of Geriatric Medical Services, Royal Melbourne Hospital
- 2002-2004 Honorary Adjunct Professor, School of Biological Sciences, University of Canberra.
- 1995- 2003 Honorary Professor, and Professorial Fellow, John Curtin School of Medical Research, Institute of Advanced Studies, Australian National University

1.3 PRINCIPAL ADMINISTRATIVE APPOINTMENTS (PREVIOUS)

- 1995-2002 Director of Geriatric Medical Services, ACT Health (until July 3, 2002)
- 1995-1999 Sub-Dean (Research), Faculty of Medicine, University of Sydney
- 1995-2001 Director, Department of Geriatric Medicine, The Canberra Hospital
- 1995-2001 Director, Aged Care Unit, The Canberra Hospital.
- 1984-1995 Director, Department of Clinical Pharmacology, Alfred Hospital, Melbourne
- 1994-1995 Acting Head of Unit, Acute Geriatric Medical Service, Alfred Hospital
- 1978-1987 Head, Clinical Pharmacology Laboratory, Baker Medical Research Institute, Melbourne
- 1974-1976 Assistant and Acting Director of Medical Services, Alfred Hospital

1.4 MAJOR POLICY AND ADVISORY APPOINTMENTS

NATIONAL

- 2002-2003 Prime Minister's Science, Engineering and Innovation Council (PMSEIC)- Working Group on Ageing and Preventive Healthcare
- 2002 Commonwealth/Victorian State Government Advisory Committee on General Practice (VACGP)/Residential Aged Care Interface Sub-Committee
- 2002-2003 National Strategy for an Ageing Australia-Building Ageing Research Capacity (BARC) Project , Expert Forum-Office of Ageing, Dept Health & Ageing
- 1998-2000 ACT Health and Community Care Representative, AMA Working Party on Safe Working Hours
- 1997-2000 ACT Health and Community Care Representative, National Medical Training Review Panel
- 1989-1994 Consultant Clinical Pharmacologist, Advisory Committee, National Accreditation & Testing Authority

1988-1993 Member, Therapeutics Advisory Committee, Royal Australasian College of Physicians

STATE

2003- Member of Management Panel, Multi Purpose Taxi Program (MPTP) (Victoria)
Medical Adviser, MPTP

2003-2005 Vision 2020 Australia - The Vision Initiative Steering Committee

1991-1992 Medical Advisory Committee to Victorian State Minister of Health

1990-1993 Member, Advisory Group on Drugs and Driving,
Vic Roads (Victorian State Government Authority)

1988-1989 Consultant Clinical Pharmacologist to Victorian Anti-Cancer Council -
Review of Andrew Durrant Toxicology Centre

1986-1987 Consultant Clinical Pharmacologist, Victorian Drug Usage Advisory
Committee to Victorian State Minister of Health

1983-1984 Member, Ministerial Working Party on Drug Use in Victorian Public
Hospitals

MAJOR INSTITUTIONAL

1991-1992 Medical Staff Representative, Board of Management, Alfred Group of
Hospitals, Melbourne, Australia

1995-2001 Member of Executive Committee, Research Advisory Committee, ACT Health and
Community Care

1995-1999 Member Research and Clinicals Trials Sub-Committee, Ethics Committee, ACT Health and
Community Care

1995-1999 Executive Member, Research Committee, Faculty of Medicine, University of Sydney

1995-1999 Graduate Entry Medical Programme- Combined Degree Committee

1994 Member, Advisory Board , Quality Education at a Distance, Monash
University, Melbourne

1978-1994 Member, Pharmacy and Therapeutics Advisory Committee, Alfred Hospital

1985-1994 Member Research & Ethics Committees A&B, Monash Medical Centre, Clayton
Campus (previously Queen Victoria Medical Centre)

1978-1994 Member, Research and Ethics Review Committee, Alfred Hospital

1993 President, Alfred Hospital Clinical Society

1991-1992 Chairman of Senior Medical Staff, Alfred Group

1990-1991 Secretary / Treasurer and Executive Member, Senior Medical Staff
Committee, Alfred Hospital Group

1988-1992 Member, Monash Medical Faculty Curriculum Review Committee

1.5 RESEARCH PROJECT ADVISORY SERVICE

INTERNATIONAL

Deutsche Forschungsgemeinschaft

Medical Research Council of Canada

Medical Research Council of New Zealand

Sandoz Foundation for Gerontological Research

NATIONAL

CSIRO – “Hospital Without Walls” Expert Advisory Panel

CSIRO Preventive Health Flagship

National Health and Medical Research Council of Australia

National Heart Foundation of Australia

Commonwealth Department of Veteran's Affairs

AMA Committee on Care of Older People

STATE

Anti Cancer Council of South Australia

Victorian Health Promotion Foundation

NSW Cancer Council

Western Australian Cancer Council

Western Australian Health Promotion Foundation

INSTITUTIONAL

University of Adelaide

University of Queensland Foundation

1.6 PREVIOUS CLINICAL APPOINTMENTS (More than 5 years past)

1995-2002	Senior Specialist Physician in General Medicine and Geriatric Medicine, The Canberra Hospital (Until July 3, 2002)
2000-2001	Consultant Physician, Greater Murray Health Service, NSW
1996-2001	Consultant Physician, Mercy Care Services, NSW
1995-2001	Director of Geriatric Medical Services, ACT Health & Director, Department of Geriatric Medicine, The Canberra Hospital
1991-1995	Consultant Physician, Acute Geriatrics Service, Alfred Hospital
1984-1994	Director, Department of Clinical Pharmacology, Alfred Hospital, Melbourne
1983-1989	Consultant Clinical Pharmacologist, Monash Medical Centre, Prince Henry's Campus (previously Prince Henry's Hospital)
1982-1988	Consultant Physician, Gastroenterology Service, Alfred Hospital
1980-1984	Clinical Pharmacologist, Alfred Hospital
1978-1987	Physician, Clinical Research Unit, Alfred Hospital
1977-1978	NHMRC Clinical Sciences Scholar (Clinical Pharmacology and Clinical Toxicology), Department of Cardiology and the Clinical Pharmacokinetics Laboratory, Buffalo General Hospital and Department of Pharmaceutics, State University of New York at Buffalo, Amherst, New York, USA
1976-1977	NHMRC Clinical Sciences Scholar (Clinical Pharmacology & Clinical Toxicology), Division of Clinical Pharmacology and Hypertension, Departments of Medicine and Pharmacology, The University of Texas Health Sciences Centre, San Antonio, Texas, USA
1975-1976	Junior Specialist Fellow in Medicine, Prince Henry's Hospital
1974	Medical Registrar, Clinical Research Unit, Vascular Medicine and Hypertension Clinic, Alfred Hospital
1973	Senior Resident Medical Officer, Prince Henry's Hospital, Melbourne
1970-1972	Clinical Assistant, Neurology Service, Alfred Hospital and Cardiology Service, Prince Henry's Hospital, Melbourne
1969	Internship, Royal Hobart Hospital

1.7 PREVIOUS ACADEMIC APPOINTMENTS

2002-2004	Honorary Adjunct Professor, School of Biological Sciences, University of Canberra.
1995- 2003	Honorary Professor, and Professorial Fellow, John Curtin School of Medical Research, Institute of Advanced Studies, Australian National University
1995-2002	Honorary Professor of Geriatric Medicine, University of Sydney, Department of Medicine, Faculty of Medicine, University of Sydney
1995-1999	Sub-Dean (Research), Faculty of Medicine, University of Sydney
1993-1999	Visiting Professor of Medicine, Christian Albrecht University Medical School, Kiel, Schleswig-Holstein, Germany
1993-1995	Honorary Professor of Clinical Pharmacology and Therapeutics, Department of Medicine Monash University

- 1992-1993 Honorary Professor of Clinical Pharmacology, Departments of Medicine and Pharmacology, Monash University
- 1982-1991 Senior Lecturer in Pharmacology, Monash University
- 1978-1991 Honorary Senior Lecturer in Medicine, Monash University Department of Medicine
- 1977-1978 NHMRC Clinical Sciences Scholar (Clinical Pharmacology and Clinical Toxicology), Department of Cardiology and the Clinical Pharmacokinetics Laboratory, Buffalo General Hospital and Department of Pharmaceutics, State University of New York at Buffalo, Amherst, New York, USA
- 1976-1977 NHMRC Clinical Sciences Scholar (Clinical Pharmacology and Clinical Toxicology), Division of Clinical Pharmacology and Hypertension, Departments of Medicine and Pharmacology, The University of Texas Health Sciences Centre, San Antonio, Texas, USA
- 1975-1976 Senior Research Fellow in Clinical Pharmacology, Monash University Department of Medicine, Prince Henry's Hospital
- 1970-1972 NH&MRC Postgraduate Fellow, Monash University Department of Physiology
- 1970-1972 Tutor-Demonstrator, Department of Physiology, Monash University
- 1970-1995 Honorary Visiting Lecturer, Department of Physiology (Integrated Cardiovascular Physiology)
- 1966-1968 Honorary Visiting Lecturer, Department of Physiology (Integrated Cardiovascular Physiology)
- 1965-1966 Tutor-Demonstrator, Department of Physiology, Monash University

1.6 TEACHING & CURRICULUM SERVICE

GRADUATE MEDICAL COURSE, UNIVERSITY OF NOTRE DAME SCHOOL OF MEDICINE (SYDNEY) 2007-

Chairman, Clinical Curriculum Committee.

Member, Basic and Clinical Sciences Domain Committee

GRADUATE MEDICAL COURSE, UNIVERSITY OF MELBOURNE 2002-2007

Chairman, Board of Studies, Rehabilitation, Aged Care, Psychiatry of Old Age, Palliative Care (RAPP) Clinical School 2001- 2002

Deputy-Chairman, Board of Studies, RAPP Clinical School 2003

UNDERGRADUATE MEDICAL COURSE , UNIVERSITY OF SYDNEY 1995-2000

Clinical Pharmacology, Fourth Year Medical Students

Geriatric Clinical Teaching, Fifth Year Medical Students

GRADUATE MEDICAL COURSE , UNIVERSITY OF SYDNEY 1995-2001

Graduate Entry Medical Programme-Curriculum Committee

Graduate Entry Medical Programme- Combined Degree Committee

UNDERGRADUATE , MONASH UNIVERSITY (1965-1994)

Monash Science Pharmacology (SCI 231)

Second year medical students, Monash University (MD 242)

Honorary Lecturer, Senior Lecturer, and Honorary Professor: Third year medical students, Monash University- Physiology and Pharmacology (1965-1992)

Fourth year medical students, Monash University- Clinical Pharmacology (1978-1994)

Fifth year medical students, Monash University- Clinical Therapeutics (1978-1994)

Sixth year medical students, Monash University- Medicinal Therapeutics (1988-1994)

Third year Science, Monash University (Pharmacology SCI 322)

Courses Co-ordinated-Monash University

Fourth year medical students "Clinical Pharmacology & Therapeutics"

Fifth year medical students "Therapeutics"

Sixth year medical students "Medicinal Therapeutics"

GRADUATE

Honours Students- Monash Departments of Physiology and Pharmacology
9 students graduated (Hons I, n=8, Hons IIA, n=1)

MSc Students- Monash Department of Pharmacology, Victorian College of Pharmacy
and RMIT Department of Applied Biology and Biotechnology
5 students graduated

PhD Students- Monash Department of Pharmacology and Victorian College of Pharmacy
5 students graduated
University of Sydney, 1 student graduated

MD Students- Christian Albrecht University, Kiel, Germany
2 students graduated

MS Students University of Sydney
1 student graduated

Post-doctoral Fellows

Professor B Heinzow, Director, Institute for Environmental Toxicology
Kiel, Germany-Functional studies of Splanchnic Blood Flow in Man and Dog
Dr Peta Harvey- NMR Studies in Hepatic Metabolism in Hepatic Cirrhosis
Dr Zhanli Yin- Structural and Functional Studies of Primary Ageing of the Liver
Professor Shu Li (Newcastle University-Chair of Pharmacy Department)-Clinical
Pharmacokinetic Studies of Aminoglycoside Antibiotic Use in Surgical Patients

POSTGRADUATE TEACHING

Faculty of Anaesthetists, Royal Australasian College of Surgeons

Victorian Medical Postgraduate Foundation

Master of Psychological Medicine, Monash University

Royal Australasian College of Physicians

Royal Australasian College of Surgeons

1.9 RESEARCH AND PUBLICATIONS

1.9.1 RESEARCH INTERESTS

Historically and currently research has been in eight major areas:

- a) mammalian circulatory control with special reference to the splanchnic vascular bed
- b) disease states and drug dosing requirement
- c) toxicology
- d) drug interactions-pharmacokinetic mechanisms
- e) drug utilisation review, drug audit and quality assurance of medicinal drug use
- f) mechanisms of antibiotic action and strategies of delivery
- g) diagnostic and therapeutic strategies in renal transplant rejection
- h) studies of primary ageing in the liver in the aged liver
- i) the biology of age-related senescence and its prevention and therapy
- ii) implications for drug metabolism and prescription use in the elderly
- iii) pathological implications of altered handling of neurotoxins
- iv) pathological and therapeutic implications of altered lipoprotein handling

1.9.2 RESEARCH ACHIEVEMENTS

1. Invention, development and characterisation of the isolated preparation of portal-mesenteric vein.
2. Developed the first evidence that action potentials in mammalian smooth muscle did not exclusively involve Na^+ channels.
3. Development of the guinea-pig as an immunisation-free model of endotoxin toxicity.
4. Proof of involvement of immunopharmacological toxicity mechanism in E. coli endotoxin toxicity.
5. Established vascular Ca^{++} -channel blockade as the mechanism of action of hydrallazine and hydrazone metabolites.
6. Established the principle of pulmonary disease as a major determinant of respiratory drug dosing requirement.
7. Established principles of food effects on first pass clearance and bioavailability of drugs with high hepatic extraction.
8. Established flow-based mechanisms of hepatic interaction between high extraction drugs.
9. Demonstrated the principle of renal tubule excretion interaction between basic drugs.
10. Developed the theory of oxygen diffusion as the rate-limiting constraint on oxidation-reduction reactions in cirrhotic livers; established flow-based mechanisms of hepatic interaction between high extraction drugs; established the quantitative effects of hepatic shunt on bioavailability of drugs with high extraction; established the sensitivity of hepatic extraction to protein binding of high extraction drugs.
11. Provided the scientific critique of management of duodenal ulcer with primary reference to relapse rate and provided evidence of systematic difference in relapse rate between classes of anti-ulcer agents.

12. Proposed the linkage between clearance of Helicobacter pylori and peptic ulcer relapse.
13. Defined optimum dosage protocols for bismuth subcitrate use. and established non-renal (hepatic) clearance as a safety factor in heavy metal safety.
14. Demonstrated principles of modification of medicinal drug use in the clinical setting via the "Hawthorne effect".
15. Demonstration of peak effect of aminoglycosides independent of area under the concentration-time curve in determining bactericidal effects. Developed a new basis for re-formulating aminoglycosides.
16. Developed the theory of oxygen diffusion as the rate-limiting constraint on oxidation-reduction reactions in aged livers; and established flow-based mechanisms for modification of hepatic oxygen supply.
17. Developed a testable hypothesis for prevention and therapy of age-related senescence in the liver
18. Developed initial guidelines for drug prescription in older people
19. Predicted and demonstrated the susceptibility of older animals to exposure to pathogenic neurotoxins as a result of altered pre-systemic hepatic clearance
20. Predicted and demonstrated age-related change in the handling of chylomicrons by the livers of older animals

1.9.3 RESEARCH GRANTS

Current

Vision 2020 Australia – The Vision Initiative- Victorian Government Department of Human Services 2006-2009

Completed

“Geriatric Pharmacology” LeCouteur DG, Cummings R, McLean AJ-NHMRC Grant 2003-2005

“The Effect of Hepatic Pseudocapillarisation of Old Age on the Disposition of Chylomicron Remnants and Chylomicrons” Le Couteur DG, Fraser R, Sullivan D, McLean AJ - NHMRC Grant 2003 –2005

"Pharmacological, metabolic and therapeutic implications of the oxygen diffusion barrier hypothesis of ageing in the liver" – Professor AJ McLean, A/Prof DG Le Couteur – DVA/NHMRC 2002 - 2004

"Assessment of hypoxia and hepatic metabolism in cirrhotic rats using NMR" AJ McLean, PJ Harvey, JE Gready - NHMRC Grant 2000 – 2004 (extended).

“Hepatic Oxygenation and Aging” - A/Prof DG Le Couteur, Professor AJ McLean, Dr Ansselin - NHMRC 1998-2000

"Assessment of hypoxia and hepatic metabolism in cirrhotic rats using NMR" AJ McLean, PJ Harvey, JE Gready – University of Sydney Bridging Grant 1997.

“Use of Nuclear Magnetic Resonance to study liver dysfunction and impaired hepatic drug metabolism in cirrhosis” - Professor A J McLean, Dr P Harvey, Dr J Gready - The Canberra Hospital Private Practice Trust Fund, 1996-1998

“Preliminary studies into the role and mechanism of action of sensory neuropeptides during vasodilation and relief from vasoconstriction” - Professor A J McLean, Dr Caryl Hill - The Canberra Hospital Private Practice Trust Fund, 1996

“Osteoporosis Study B3D-MC-GHAC” - Professor A J McLean, Dr M Davis - Eli Lilly, 1996

“Hepatic artery perfusion in isolated rat livers” - Professor A J McLean, H Hickey, The Canberra Hospital Private Practice Trust Fund , 1995

“Diltiazem in hepatic cirrhosis in rats” - Professor A J McLean - ICI (Australia), 1994 - 1996

"Interactions between calcium channel blockers and beta-adrenoceptor antagonists" - Dr A J McLean. National Institutes of General Medical Sciences, National Institutes of Health (USA), 1989-1994

"Influence of diltiazem on hepatic artery flow in normal and cirrhotic animals- correlation with therapeutic effects " - Dr A J McLean. ICI Australia, 1993-1994

"Interactive Computer Simulations of Pharmacokinetics for Scenarios in Clinical Pharmacology" - Professor B Jarrott, Dr A J McLean. Committee for the Advanced of University Teaching. Monash University, 1993-1994

"Mechanism of Action of Aminoglycosides on Pseudomonas Auerogenosa"- Alfred Hospital Research Trust Funds 1994-1995

"A novel method for assessment of cardiac conduction tissue: variation of electrograms with anisotropic propagation" - Dr A Tonkin, Dr A J McLean, Dr E Blakshi. National Heart Foundation of Australia. 1991-1993

"Optimisation of Aminoglycoside Use"- Dr A J McLean. Alfred Hospital Medical Research Scholarship, 1993

"A study to examine the margin of safety between the present ADI (Acceptable Daily Intake) of fenitrothion and its no-effect level in humans" - Prof JJ McNeill & Dr A J McLean. Australian Wheat Board, 1990-1993

"A study to compare the clinical efficiency of Denol chewable versus Denol coated tablets in the absorption of bismuth in patients suffering from duodenal ulcer" - Dr J Lambert & Dr A McLean. Gist-Brocades Pharmaceuticals, 1990-1991

"Verification and application of mathematical models of function of the sinus node and AV junction in conscious and anaesthetised animals" - Dr A J McLean & Dr A Tonkin. National Heart Foundation of Australia, 1990-1991

"A novel study of the microbiological basis and clinical cost benefits of the first exposure and post-antibiotic effects of aminoglycosides and alternative antibiotics" - Mr S C Li, Dr L Ioannides-Demos, Dr W J Spicer, Dr G Bowes, Dr D W Spelman, Mr N Tong, Dr A J McLean. Alfred Hospital Medical Research Scholarship, 1990

"Mechanism of the differential effect of sustained release and conventional dose forms of nicotinic acid in rats" - Dr A J McLean. Rhône- Poulenc Australia Ltd, 1990

"A study of the pharmacokinetics of nicotinic acid in patients on chronic nicotinic acid therapy" - Dr A J McLean. Auspharm International Limited, 1989

"Optimising combination dosing with major cardiovascular drugs" - Dr A J McLean. NH&MRC, 1988-1990

"Aminoglycoside antibiotic dosing in defined groups of high risk patients - efficacy, toxicity and cost benefit analysis" - Ms L Ioannides-Demos, Dr W J Spicer, Dr P M Harrison, Dr F W Gurr, Mr S C Li, Dr J Sabto, Dr G Bowes, Mr N Tong, Dr D Spelman, Dr A J McLean. Alfred Hospital Medical Research Scholarship, 1988

"A comparative study of the pharmacokinetic profiles of enalapril and lisinopril, with and without co-administration of hydralazine" - Dr A J McLean. ICI Australia, 1987

"Cefotetan Clinical Trial" - Dr A J McLean. ICI Australia, 1987

"An investigation of potential drug interactions involving Phase II metabolism (conjugation pathways) - Dr P M Harrison and Dr A J McLean. Alfred Hospital Medical Research Scholarship, 1986

"Audit of therapeutic drug use in a general hospital" - Ms L Ioannides-Demos, Mr N Tong, Dr A J McLean. Alfred Hospital Medical Research Scholarship, 1984-1985

Drug interactions involving medications with high hepatic clearance - Dr A J McLean. NH&MRC, 1984-1985

"Influence of cirrhosis and decompressive shunt surgery on hepatic function and hepatic blood flow" - Dr A J McLean, Mr W I Johnson, Dr F J Dudley, Mr I McInnes. Alfred Hospital Medical Research Scholarship, 1982-1983

"Drug assay services and therapeutic drug use in a general hospital" - Dr A J McLean, Mr N Tong, Ms L L Ioannides-Demos. Alfred Hospital Medical Research Scholarship, 1982-1983

"Hypertension & circulatory control" - PI Korner & Associates. NH&MRC, 1979-1983

University of Texas Health Sciences Fellowship Support Award, 1977

Clinical Sciences Fellowship (Clinical Pharmacology), NH&MRC, 1976-1978

Medical Postgraduate Scholarship, NH&MRC, 1969-1972

2.0 PROFESSIONAL ACTIVITIES

MEMBERSHIP OF PROFESSIONAL ASSOCIATIONS AND LEARNED SOCIETIES

Australian Society for Geriatric Medicine

Australian Association of Gerontology

Australasian Society of Clinical and Experimental Pharmacology and Toxicology

Australasian and New Zealand Association for Medical Education

American Society for Clinical Pharmacology & Therapeutics

American Society for Microbiology

American Association for The Advancement of Science

REFEREE FOR SCIENTIFIC JOURNALS

Alimentary Pharmacology and Toxicology

Australian and New Zealand Journal of Medicine (now Internal Medicine Journal)

Australian Journal of Hospital Pharmacy

Clinical and Experimental Pharmacology and Physiology

Drug Investigation

Gastroenterology

Hepatology

Journal of Hepatology and Gastroenterology

Journal of Human Hypertension

Journal of Pharmaceutical Sciences

Journal of Pharmacology and Experimental Therapeutics

Medical Journal of Australia

Saudi Medical Journal

Pharmacoeconomics

Drugs & Therapy Perspectives (Foundation Editorial Board Member)

Editorial Board Member: Geriatric Medicine-Continuing Medical Education (UK)

REFEREED PUBLICATIONS EXCLUDING ABSTRACTS

1. McLean AJ. The pharmacology of an isolated neuro-muscular preparation of sheep mesenteric veins. B Med Sci Thesis, Monash University, (1965).
2. Chapman, JB & McLean AJ. An Electrophysiological Study of the 'd' Response in Cat Spinal Cord. BMedSci Thesis, Monash University, (1965).
3. Holman ME & McLean AJ. The innervation of sheep mesenteric veins. J.Physiol. 190: 55-69, (1967).
4. Hashimoto Y, Holman ME, McLean A. The effect of tetrodotoxin on the electrical activity of smooth muscle of vas deferens. Nature 215: 430-432, (1967).
5. Holdsworth S, McLean A, Morris BJ, Dax E, Johnston CI. Renin release from isolated rat glomeruli. Clin. Sci. Mol. Med. 51: 97-99, (1976).
6. Perceval A, McLean AJ, Wellington CV. Emergence of gentamicin resistance in Staphylococcus aureus. Med J Aust. 10;2:74-5, (1976).
7. Bobik A & McLean AJ. Cardiovascular complications of pheniramine overdose. Aust. N.Z. J. Med. 6: 65-67, (1976).
8. McLean AJ. The actions of endotoxins in guinea pigs. Ph.D. Thesis, Monash University, (1976).
9. Barnett AJ, Bobik A, Carson V, Korman J, McLean AJ. Pharmacokinetics of alpha-methyl-dopa. Plasma levels after single intravenous, oral and multiple dosage. Clin. Exp. Pharmacol. Physiol. 4: 331-339, (1977).
10. Bobik A & McLean AJ. Drug analysis in the overdosed patient, its application to clinical toxicology. Med. J. Aust. 1: 367-369, (1977).
11. McLean AJ. Anaphylactic reactions to endotoxin in guinea pig tissue. Relationship to endotoxin toxicity. Brit. J. Pharmacol. 60: 369-373, (1977).
12. McLean AJ & Boquest A. Enteric flora of normal laboratory guinea pigs. Brit. J. Exp. Pathol. 58:251-254, (1977).
13. McLean AJ. Relationship between E. Coli endotoxin toxicity and immunization status of normal adult guinea pigs. Brit. J. Exp. Pathol. 58: 255-259, (1977).
14. McLean AJ, Haegele KD, du Souich P, McNay JL. Comparative evaluation of the hypotensive activity of two major metabolites of hydralazine (1-hydralazinophthalazine) Eur. J. Drug Metab. Pharmacokinet. 1: 1-6, (1977).

15. Barron K, Carrier O, Haegele KD, McLean AJ, McNay JL, du Souich P. Comparative evaluation of the in vitro effects of hydralazine and hydralazine acetonide on arterial smooth muscle. *Brit. J. Pharmacol.* 61: 345-9, (1977).
16. Haegele KD, McLean AJ, du Souich P, Barron K, Laquer J, McNay JL, Carrier O. Identification of hydralazine and hydralazine hydrazone metabolites in human body fluids and quantitative in vitro comparisons of their smooth muscle relaxant activity. *Brit. J. Clin. Pharmacol.* 5: 489-494, (1978).
17. McLean AJ, Barron K, du Souich P, Haegele KD, McNay JL, Carrier O, O'Briggs A. Interaction of hydralazine and hydrazone derivatives with contractile mechanisms in rabbit aortic smooth muscle. *J. Pharmacol. Exp. Ther.* 205: 418-425, (1978).
18. McLean AJ & Dowling J. Type III (Arthus) allergic reactions and endotoxin toxicity in guinea-pigs. *Experientia* 34: 236-7, (1978).
19. du Souich P, McLean AJ, Lalka D, Erril S, Gibaldi M. Pulmonary disease and drug kinetics. *Clin. Pharmacokinet.* 3: 257-266, (1978).
20. Lalka D, du Souich P, McLean AJ, Gibaldi M. Absolute drug bioavailability II - Evaluation of the renal clearance perturbation method. *J. Pharm. Sci.* 67: 591-592, (1978).
21. McLean AJ. Study of the 'in vitro' pharmacology of gram-negative endotoxins in parallel with toxicity testing in normal adult guinea pigs. *Clin. Exp. Pharmacol. Physiol.* 5: 151-9, (1978).
22. du Souich P, McLean AJ, Lalka D, Jenkins B, Haegele KD, McNay JL. Sulfadiazine handling in the rabbit I Pseudo-saturation of N-acetyltransferase, a renal phenomenon. *J. Pharmacol. Exp. Ther.* 207: 221-227, (1978).
23. McLean AJ, McNamara P, du Souich P, Gibaldi M, Lalka D. Food, splanchnic blood flow and bioavailability of drugs subject to first-pass metabolism. *Clin. Pharmacol. Ther.* 24: 5-10, (1978).
24. du Souich P, McLean A J, Lalka D, Vicuna N, Chaudhuri E, McNay JL. Sulfadiazine handling in the rabbit II Mechanisms of non-linear kinetics of elimination. *J. Pharmacol. Exp. Ther.* 207: 228-235, (1978).
25. McLean AJ, Barron K, du Souich P, Briggs A. Interaction of hydralazine with tension development and mechanisms of calcium accumulation in K⁺ stimulated rabbit aortic strips. *J. Pharmacol. Exp. Ther.* 207: 40-48, (1978).
26. du Souich P, Lalka D, McLean AJ, Vicuna A, McNay JL. Comparison of screening methods for determination of N4-acetyl-transferase capacity (acetylator phenotype) in outbred rabbit strains. *J. Lab. Clin. Med.* 92: 290-296, (1978).

27. McLean AJ, du Souich P, Barron K, Carrier O, Haegele KD, McNay JL. Study on in vitro effects of hydralazine metabolites - comparative evaluation of products of hydroxylation, hydrolysis and conjugation. *Arch. Int. Pharmacodyn.* 235: 19-25, (1978).
28. Vicuna N, Lalka D, Burrow SR, McLean AJ, du Souich P, McNay JL. Dose-dependent pharmacokinetic behaviour of lidocaine in the conscious dog. *Res. Commun. Chem. Pathol. Pharmacol.* 22: 485-491, (1978).
29. Taylor JW, McLean AJ, Leonard RG, Ludden TM, Clibon U, du Souich BP, Harris SC, Lalka D, Talbert RL, Vicuna N, Walton CA, McNay JL. Initial experience of clinical pharmacology and clinical pharmacy interactions in a clinical pharmacokinetic consultation service. *J Clin Pharmacol* 19: 1-7. (1979).
30. McLean AJ, du Souich P, Gibaldi M. Non-invasive pharmacokinetic method for the estimation of total hepatic blood flow and the degree of shunting of blood in patients with chronic liver disease - a hypothesis. *Clin. Pharmacol. Ther.* 25: 161-166, (1979).
31. Taylor J, McLean AJ, Leonard R, Clibon U, du Souich P, Harris S, Lalka D, Ludden T, Talbert R, Vicuna N, Walton C, McNay JL. Initial experience of clinical pharmacology and clinical interactions in a clinical pharmacokinetics consultation service. *J. Clin. Pharmacol.* 19: 1-7, (1979).
32. du Souich P, Lalka D, Slaughter R, Elvin AT, McLean AJ. Mechanisms of non-linear disposition kinetics of sulfamethazine in normal volunteers. *Clin. Pharmacol. Ther.* 25: 172-183, (1979).
33. du Souich P, McLean AJ, Stoeckel KM, Olhendorf D, Gibaldi M. Screening methods using sulfamethazine for determining acetylator phenotype. *Clin. Pharmacol. Ther.* 26: 757-765, (1979).
34. Stockel KM, McNamara PJ, McLean AJ, du Souich P, Lalka D, Gibaldi M. Non-linear pharmacokinetics of indocyanine green in the rabbit and rat. *J. Pharmacokinet. Biopharm.* 8: 483-496, (1980).
35. McLean AJ, Skews H, Bobik A, Dudley FJ. Interaction between oral propranolol and hydralazine-mechanisms and therapeutic implications. *Clin. Pharmacol. Ther.* 27: 726-732, (1980).
36. Vicuna A, Lalka D, Su Souich P, Vicuna N, Ludden TM, McLean AJ. Dose-dependence of the apparent half-life of phenytoin in the rat. *Res Commun Chem Pathol Pharmacol.* 28:3-11 (1980).
37. Guest K, McLean AJ, Wellington CV. Drug assay services and therapeutic drug use in a general hospital. *Med. J. Aust.* 1: 167-170, (1980).
38. Elvin AT, Lalka D, Stoeckel K, du Souich P, Axelson JE, Golden LH, McLean AJ. Tocainide kinetics and metabolism: effects of phenobarbital and substrates of glucuronyl transferase. *Clin Pharmacol Ther.* 28: 652-8 (1980).

39. McLean AJ, Isbister C, Bobik A., Dudley FJ. Reduction of first-pass hepatic clearance of propranolol by food. *Clin. Pharmacol. Ther.* 30: 31-34, (1981).
40. Bobik A, Jennings G, Skews H, Esler M, McLean A. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypertension. *Clin. Pharmacol. Ther.* 30: 673-679, (1981).
41. Jackman GP, McLean AJ, Jennings GL, Bobik A. No stereoselective first-pass hepatic extraction of propranolol. *Clin. Pharmacol. Ther.* 30: 291-296, (1981).
42. Ioannides L, Somogyi A, Spicer J, Heinzow B, Tong N, Franklin C, McLean AJ. Rectal administration of metronidazole provides therapeutic plasma levels in post-operative patients. *New Engl. J. Med.* 305: 1569-1570, (1981).
43. du Souich P, McLean AJ, Lalka D, Erril S, Gibaldi M. Pulmonary disease and drug kinetics. In: *Topics in Clinical Pharmacology*, ed. G.S. Avery, Sydney, Adis Press Australasia, (1981).
44. McLean AJ, Ioannides-Demos L, Tong N, Mercer W, Barned J, Wood TJ. Audit and scientific management of drug use in an Australian teaching hospital. *Aust. Health Review* 5: 12-15,(1982).
45. Colman JC, Jennings GL, McLean AJ, Mignot P, Dudley F.J. Propranolol in decompensated alcoholic cirrhosis. *Lancet* 2: 1040-1041, (1982).
46. McLean A. Rectal administration of metronidazole - reply. *N. Engl. J. Med.* 307: 121-122, (1982).
47. McLean AJ, Ioannides-Demos L, Somogyi A, Tong N, Spicer J. Successful substitution of rectal metronidazole administration for intravenous use. *Lancet* 1: 41-43, (1983).
48. Ioannides-Demos L, Somogyi A, Tong N, Spicer J, McLean AJ. Clinical pharmacy monitoring and utilisation of enteral and parental metronidazole in a general hospital. *Aust. J. Hosp. Pharm.* 13: 4-7, (1983).
49. McLean AJ & Melander A. The influence of food and oral drug usage. *Current Therapeutics* 24: 51-58, (1983).
50. Melander A & McLean AJ. Influence of food intake on presystemic clearance of drugs. *Clin. Pharmacokinet.* 8(4): 286-296, (1983).
51. McLean AJ, Wilhelm D, Heinzow BJ. Stable oral availability of atenolol coadministered with hydralazine. Comparison with propranolol, metoprolol and other beta-adrenoceptor antagonists. *Drugs* 25(2): 131-135, (1983).

52. McLean AJ, Gelman J, Hargreaves M, Jennings GL. Interaction of methyl dopa with autonomic reflex tachycardia in man. *J. Cardiovasc. Pharmacol.* 5: 638-642, (1983).
53. Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. *Eur. J. Clin. Pharmacol.* 25: 339-345, (1983).
54. Somogyi A, Kong C, Sabto J, Gurr FW, Spicer WJ, McLean AJ. Disposition and removal of metronidazole in patients undergoing haemodialysis. *Eur. J. Clin. Pharmacol.* 25: 683-687, (1983).
55. du Souich P, McLean AJ, Lalka D, Erill S and Gibaldi M: Pulmonary disease and pharmacokinetics. In *The Handbook of Clinical Pharmacokinetics*, ed Gibaldi M. ADIS Health Science Press, New York, NY pp III 201-211 (1983)
56. Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ. Stable oral availability in man of sustained released propranolol (Inderal LA) coadministered with hydrallazine or food - Evidence implicating substrate delivery rate as a determinant of presystemic drug interactions. *Brit. J. Clin. Pharmacol.* 17(supp.1) : 45S-50S, (1984).
57. Collier G, McLean A, O'Dea K. The effect of co-ingestion of fat on the metabolic responses to slowly and rapidly absorbed carbohydrates. *Diabetologia* 26: 50-54, (1984).
58. Somogyi AA, Kong CB, Gurr FW, Sabto J, Spicer WJ, McLean AJ. Metronidazole pharmacokinetics in patients with acute renal failure. *J. Antimicrob. Chemother.* 13: 183-190, (1984).
59. Efthimiou H, Morgan DJ, Ioannides-Demos L, Raymond K, McLean AJ. Influence of chronic dosing on Theophylline clearance. *Br. J. Clin. Pharmacol.* 17: 525-530, (1984).
60. McLean, A.J., Ioannides-Demos, L.L., Spicer, W.J.: Current clinical applications and dose regimens of metronidazole and related nitroimidazoles. *Med.J. Aust.* 141: 163-166, (1984).
61. McLean AJ. Sampling time for therapeutic drug monitoring. *Aust. Prescriber.* 7(1): 16-17, (1984).
62. McLean AJ, Harrison PM, Ioannides-Demos L, Byrne AJ, McCarthy P, Dudley FJ. Letter - Microbes, peptic ulcer, relapse rates with different drugs. *Lancet* 2: 525-526, (1984).
63. Ruffin R, Albers J, Henderson G, Crockett A, McLean A. Effect of varying plasma concentrations of beta-blockers on the airway function of asthmatics. *Aust. N.Z. J. Med.* 14: 533S-534S, (1984).
64. Melander A & McLean A. Effect of food on the absorption and metabolism of drugs. *Internal Medicine for the Specialist* 5: 51-60, (1984).

65. McLean AJ. Rational choice of drugs for ulcer therapy, Letter - Med. J. Aust. 141: 726-727, (1984).
66. McLean AJ, Ioannides-Demos LL, Spicer WJ. Cost of nitroimidazoles, Letter - Med. J. Aust. 141: 601-602, (1984).
67. McLean AJ, Barned J, Ioannides-Demos L, Nel D, Tong N, Mercer W, Wood TJ. Computer based prescription audit as a research, education and management tool. Aust. Health Review 7: 260-268, (1984).
68. Heinzow BJ, Corbett H, Constantinides S, Bourne R, McLean AJ. Interaction between oral hydralazine and propranolol pharmacokinetics. I. Changes in absorption, presystemic clearance and splanchnic blood flow. J. Pharmacol. Exp. Ther. 229: 509-514, (1984).
69. McLean AJ, Tonkin A, McCarthy P, Harrison PM. Dose-dependence of atenolol-ampicillin interaction. Brit. J. Clin. Pharmacol. 18: 969-971, (1984).
70. Byrne AJ, Morgan DJ, Harrison PM, McLean AJ. Variation in hepatic extraction with unbound drug fraction discriminates between models of hepatic drug elimination. J. Pharm. Sci. 74: 205-207, (1985).
71. McLean AJ., McCarthy P, Dudley FJ. Cytoprotective Agents and Ulcer Relapse. Med.J. Aust. 142: S25-S28, (1985).
72. McLean AJ., McCarthy P, Dudley FJ. Cytoprotective Agents and Ulcer Relapse. Med.J. Aust. 142: S: S25-S28, (1985).
73. Harrison PM, Tonkin AM, McLean AJ. The determination of 4-amino-3-(p-chlorophenyl) butyric acid (baclofen) in plasma by high performance liquid chromatography. J. Chromatogr. 339: 424-428, (1985).
74. Harrison PM, Tonkin AM, McLean AJ. Simple and rapid analysis of atenolol and metoprolol in plasma using solid phase extraction and high performance liquid chromatography. J. Chromatogr. 339: 429-433, (1985).
75. McLean AJ. Drug usage in patients with liver disease. Saudi Med. J. 6: 1-2, (1985).
76. Ioannides-Demos LL, McLean AJ, Wodak J, Tong N, Heinzow U, Horne M, Harrison PM, Gilligan BS. Availability of drug assay results and dosage advice improves antiepileptic care in a specialist neurology outpatient clinic. Clin. Exp. Neurol. 21: 171-176, (1985).
77. McLean AJ, Harrison PM, Ioannides-Demos L, Byrne AJ, McCarthy P, Dudley FJ. The choice of ulcer healing agent influences duodenal ulcer relapse rate and long-term clinical outcome. Aust. N.Z. J. Med. 15: 367-374, (1985).

78. Harrison PM, Tonkin AM, Cahill CM, McLean AJ. Rapid and simultaneous extraction of propranolol, its neutral and basic metabolites from plasma and assay by high performance liquid chromatography. *J. Chromatogr.* 343: 349-358, (1985).
79. McLean AJ, Harrison PM, Byrne AJ, McCarthy P, Dudley FJ. Relapse rates are more important than healing rates in determining the long-term outcome of duodenal ulcer therapy. *Gastroenterology* 89: 480-481, (1985).
80. McLean AJ, Knight R, Harrison PM, Harper RW. Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol. *Am. J. Cardiol.* 55: 1623-1629, (1985).
81. Melander A, Liedholm H, McLean AJ. Concomitant food intake does enhance the bioavailability and effect of hydralazine (letter). *Clin. Pharmacol. Ther.* 38: 475, (1985).
82. Morgan DJ, Raymond K and McLean AJ. Influence of chronic dosing on theophylline clearance. *Br J Clin Pharmacol.* 19: 713, (1985).
83. Harrison PM, Tonkin AM, Dixon ST, McLean AJ. Determination of debrisoquine and its 4-hydroxy metabolite in urine by high performance liquid chromatography. *J. Chromatogr.* 374: 204-208, (1986).
84. Harrison PM, Tonkin AM, Dixon ST, McLean AJ. Determination of alpha-naphthoxylactic acid, a major metabolite of propranolol, in plasma by high-performance liquid chromatography. *J. Chromatogr.* 374: 223-225, (1986).
85. McLean AJ & Melander A. Meals and medications. *Australian Prescriber* 9(3): 68, (1986).
86. Gibson R, McLean AJ, Dudley FJ. The hypotensive effect of nitroglycerine on portal venous pressure in patients with cirrhotic portal hypertension. *J. Gastroenterology and Hepatology.* 1: 201-206, (1986).
87. Eaves ER, Hansky J, Cahill CM, Ward F, Mercuri J, McLean AJ. The role of the liver in the metabolism of neurotensin-like immunoreactivity in man and dog. *J. Gastroenterology and Hepatology.* 1: 229-236, (1986).
88. Keech, AC, Harper RW, Harrison PM, Pitt A, McLean AJ. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris. *Am. J. Cardiol.* 58: 551-552, (1986).
89. Corbett H, Cahill CM, Heinzow BJ, Harrison PM, McLean AJ. Interaction between oral hydralazine and propranolol pharmacokinetics. II Assessment of altered splanchnic blood flow as the determinant of altered presystemic extraction. *J. Pharmacol. Exp. Ther.* 239: 517-521, (1986).
90. McMillan DA, Harrison PM, Rogers LJ, Tong N, McLean AJ. Polypharmacy in an Australian teaching hospital - Preliminary analysis of prevalence, elements and associations. *Med. J. Aust.* 145: 339-342, (1986).

91. Rabinov M, Rosenfeldt FL, McLean AJ. A Double-blind comparison of the relative efficacy, side-effects and cost of buprenorphine and morphine in patients after cardiac surgery. *ANZ J.Surg.* 57: 227-231, (1987).
92. McLean AJ, Harcourt DM, McCarthy PM, Dudley FJ, McNeil JJ. Relative effectiveness and costs of antiulcer medications as a basis for rational prescribing. *Med. J. Aust.* 146: 431-442, (1987).
93. Heinzow BGJ, Somogyi A, McLean AJ. Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. *Arch int Pharmacodyn. Ther* 286: 5 - 14, (1987).
94. McLean AJ (Editorial). The influence of relapse rate on the choice of duodenal ulcer therapy. *Drug and Therapeutics Bulletin* 25: 77-80, (1987).
95. Keech AC, Harrison PM, McLean AJ. Simple extraction of atenolol from urine and its determination by high performance liquid chromatography. *J. Chromatogr.* 426: 234 - 236, (1988).
96. Froomes PRA, Wan AT, Harrison PM, McLean AJ. Improved assay for determination of bismuth in biological samples using atomic absorption spectrophotometry with hydride generation. *Clin. Chem.* 34 (2): 382 - 384, (1988).
97. McLean AJ, Harcourt DM, McNeil JJ. Relapse rate as a major determinant of drug selection in peptic ulcer therapy. *Drugs* 35: 329 - 333, (1988).
98. McLean AJ. Factors influencing prescribing - the role of the Hospital Pharmaceutical Advisory Committee and Drug Formulary. *Aust. J.Hosp.Pharm.* 18 (Suppl): 22, (1988).
99. Ioannides-Demos LL, Horne M, Tong N, Wodak J, Harrison PM, McNeil JJ, Gilligan BS, McLean AJ. Impact of a pharmacokinetics consultation service on clinical outcomes in an ambulatory care epilepsy clinic. *Am J Hosp Pharm.* 45: 1549 - 1551, (1988).
100. Wood LJ, Massie D, McLean AJ, Dudley FJ. Renal sodium retention in cirrhosis: tubular site and relation to hepatic dysfunction. *Hepatology.* 8: 831- 836, (1988).
101. Melander A, Lalka D, McLean AJ. Influence of food on the presystemic metabolism of drugs. *Pharmac. Ther.* 38: 253 - 267, (1988)
102. Keech AC, Harper RW, Harrison PM, Pitt A, McLean AJ. Extent and pharmacokinetic mechanism of oral atenolol - verapamil interaction in man. *Eur. J. Clin. Pharmacol.* 35: 363-367, (1988).
103. Jenkins MA, Hurley SF, Jolley DJ, Oliver RG, McLean AJ, McNeil JJ. Trends in Australian mortality of asthma, 1979-1985. *Med. J. Aust.* 149: 620-624, (1988).

104. McLean AJ & Power J. Meals and medications versus food-drug interactions. *Proc. Nutr. Soc. Aust.* 13: 55-60, (1988).
105. Briggs RJS, Rundle HPM, Hooper R, Spicer WJ, McLean AJ. Antibiotic prophylaxis in nasal and minor oropharyngeal surgery - an evaluation of single dose versus five day prophylaxis. *J. Otolaryng. Soc. Austral.* 6 (2): 85-87, (1988.).
106. McLean AJ. The Pharmaceutical Benefits Scheme. *Med J Aust.* 149: 716-717 (1988).
107. Li SC, Ioannides-Demos LL, Harrison PM, Spicer WJ, Spelman DW, Tong N, Hargreaves AP, McLean AJ. Case applications of a computer-aided aminoglycoside therapeutic monitoring technique. *Aust. J Hosp. Pharm.* 19: 147-153, (1989).
108. Li SC, Ioannides-Demos LL, Spicer WJ, Berbatis C, Spelman DW, Tong N, McLean AJ. Prospective audit of aminoglycoside usage in a general hospital with assessment of clinical processes and adverse clinical outcomes. *Med J Aust.* 151: 224-232, (1989).
109. McLean AJ, Drummer OH, Smith HJ, Froomes P, McNeill JJ. Comparative pharmacokinetics of enalapril and lisinopril, given alone and with hydralazine. *Journal of Human Hypertension* 3 (Supp 1): 147-151, (1989).
110. Froomes PRA, Wan AT, Keech AC, McNeil JJ, McLean AJ. Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthate. *Eur. J. Clin. Pharmacol.* 37: 533-536, (1989).
111. Lambert J R & McLean AJ. Pathogenicity of *Campylobacter pylori* in the upper gastrointestinal tract - implications for modern therapy. *Med J Aust* 151: 120-122, (1989).
112. Ioannides-Demos LL, Farmer C, Spicer WJ, McLean AJ. Design and trial of a metronidazole loading dose regimen for patients undergoing emergency surgery. *ANZ J Surg.* 59: 55-59, (1989).
113. Smith H, McLean AJ. Calcium antagonist drugs in the management of cardiovascular disease. *Med J Aust.* 151(5) : 302 (1989)
114. McLean AJ, Islam S, Lambert JR. Anomalous short plasma elimination half-life in a patient intoxicated with bismuth subcitrate. *Gut* 31 (9): 1086, (1990).
115. Islam S & McLean A J. Systemic chemotherapy for *Helicobacter pylori* eradication? *Gut* 31 (12): 1421-1422, (1990).
116. McLean AJ & Morgan DJ. Clinical pharmacokinetics in patients with liver disease. *Clinical Pharmacokinetics* 21: 42-69, (1991).

117. Eckert, GM, Ioannides-Demos LL, McLean AJ. Measuring and modifying hospital drug use. *Med J Aust* 154: 587-592, (1991).
118. Huntington PJ, Seneque S, Slocombe RF, Jeffcott LB, McLean AJ, Luff AR. Use of phenytoin to treat horses with Australian stringhalt. *Aust Vet J* 68: 221-224, (1991).
119. Morgan DJ & McLean AJ. Therapeutic implications of impaired hepatic oxygen diffusion in chronic liver disease. *Hepatology* 14: 1280-1282, (1991).
120. Murthy SS, Nelson WL, Shen DD, Power JM, Cahill CM, McLean AJ. Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. 19: 1093 - 1100, (1991).
121. Li SC, Bowes G, Ioannides-Demos LL, Spicer WJ, Hooper RE, Spelman DW, Tong N, McLean AJ. Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients. *J Antimicrob Chemother* 28: 561-568, (1991).
122. McLean AJ. The "Hawthorn Effect" during therapeutic studies in a tertiary referral hospital. *Aust. Prescriber* 14 (Supp 1): 56-57, (1991).
123. Ioannides-Demos LL, Eckert GM, McLean AJ. Pharmacoeconomic consequences of measurement and modification of hospital drug use. *Pharmacoeconomics*. Vol. 2, No 1 : 15 - 33, (1992).
124. Li SC, Ioannides-Demos LL, Spicer WJ, Spelman DW, Tong N, McLean AJ. Prospective audit of an aminoglycoside consultative service in a general teaching hospital. *Med J Aust*. 157: 308-311, (1992).
125. Corvaia L, Li SC, Ioannides-Demos LL, Bowes G, Spicer WJ, Spelman DW, Tong N, McLean AJ. A prospective study of the effects of oral probenecid on the pharmacokinetics of intravenous ticarcillin in patients with cystic fibrosis. *J Antimicrob Chemother*. 30: 875-878, (1992).
126. McLean AJ. Drug availability revisited: notification of clinical trials. *Med J Aust* 156 : 70 (1992)
127. McLean AJ. Why does Australia have no national drug policy? *Med J Aust* 157: 32-33 (1992)
128. Bastone EB, Li SC, Ioannides-Demos LL, Spicer J, McLean AJ. Kill kinetics and regrowth patterns of *E. coli* exposed to gentamicin concentration-time profiles simulating in vivo bolus or infusion dosing. *Antimicrob Agents Chemother*. 37: 914-917, (1993.).
129. McLean AJ, Ioannides-Demos LL, Li SC, Bastone EB, Spicer WJ. Bactericidal effect of gentamicin peak concentration provides a rationale for administration of bolus doses. *J Antimicrob Chemother*. 32: 301-305, (1993.).

130. McLean AJ, Bastone EB, Ioannides-Demos LL, Spicer WJ. Bactericidal effect of gentamicin trough concentration provides a rationale for administration of bolus doses and maintenance of trough levels. *J Antimicrob Chemother.* 33:999-1004, (1994).
131. McLean AJ., Ioannides-Demos L.L., Topliss D, Tong N. Drug rationing in a teaching hospital: *Br Med J.* 309:54, (1994).
132. Heinzow BGJ., McLean AJ. Critical evaluation of current concepts in exposure assessment. *Clin. Chem.* 40: 1368-1375, (1994).
133. Ioannides-Demos LL, Li SC, Bastone EB, Spelman DW, Hooper RE, Cousins VC, McLean AJ. Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin. *J Antimicrob Chemother.* 34: 267-274, (1994).
134. McLean AJ. Flexner revisited and Australian health-care change-letter from Germany and Britain. *Royal Australasian College of Physicians Fellowship Affairs.* 13(4): 43-45, (1994).
135. Luppino M., McLean AJ. Plasma and tissue distribution of bismuth in normal and cirrhotic rats. *Analyst* 120 (3): 883-886, (1995).
136. McLean AJ, Ioannides-Demos LL. Aminoglycoside dosing: time to change *ANZ J Med* 25 (2): 175, (1995).
137. Power J M, Morgan D J, McLean A J. Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. *Biopharm. Drug Dis.* 16:579-589 (1995).
138. Morgan D J, McLean A J. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. *Clin. Pharmacokinet.* 29:370-391 (1995).
139. Ioannides-Demos L L, Liolios L, Topliss D J, McLean A J. A prospective audit of total parenteral nutrition at a major teaching hospital. *Med J. Aust.* 163:233,235-237 (1995).
140. McLean A J, Ioannides-Demos L. Aminoglycoside dosing: time to change. *Aust. N.Z. J. Med* 25:175-176 (1995).
141. Proppe D G, Hoch O D, McLean A J, Visser K E. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. *Br. J. Clin. Pharmacol.* 39:337-338 (1995).
142. McLean A J, Liolios L, Bastone E B, Ioannides-Demos L L, Spicer W J, Christophidis N. Concentration dependence of gentamicin post-bolus peak effect on *Escherichia coli* kill kinetics. *J. Antimicrob. Chemother.* 35:444-446 (1995).
143. Hickey P L, Angus P W, McLean A J, Morgan D J. Oxygen supplementation restores theophylline clearance to normal in cirrhotic rats. *Gastroenterology* 108:1504-1509 (1995).

144. McLean A J Upper gastrointestinal tract. *Med.J.Aust.* 162:387-8 (1995).
145. Proppe DG, Jentzen V, McLean AJ. Diagnostic value of urinary thromboxane B2 concentration in detection of initial acute rejection reactions human renal allografts. *Transplantation* 59: 1057-9 (1995).
146. Wood P J, Ioannides-Demos L L, Li S C, Williams T J, Hickey B, Spicer W J, Hooper R E, McLean A J. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. *Thorax* 51:369-373 (1996).
147. McLean A J, Ioannides-Demos L L, Spicer W J, Christophidis N. Aminoglycoside dosing: one, two or three times a day? *Med.J.Aust.* 164:39-42 (1996)
148. Flamer H E, Christophidis N, Margetts C, Ugoni A, McLean A J. Extended hospital stays with increasing age: the impact of an acute geriatric unit. *Med.J.Aust.*164:10-13 (1996).
149. Wood P J, Ioannides-Demos L L, Bastone E B, Spicer W J, McLean A J. Kill kinetics and regrowth patterns of *Pseudomonas aeruginosa* exposed to tobramycin concentration time profiles simulating in vivo bolus or infusion dosing. *Antimicrob.Ag.Chemother.*40:1321-1324 (1996).
150. Hickey PL, McLean AJ, Angus P W, Choo E F, Morgan DJ. Increased sensitivity of propranolol clearance to reduced oxygen delivery in the isolated perfused cirrhotic rat liver. *Gastroenterology* 111: 1039-1048 (1996).
151. Ioannides-Demos LL, Christophidis N, Ryan P, Angelis P, McLean AJ Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. *Rheumatol.*; 24(1): 49-54 (1997).
152. Le Couter D G, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. *Clin Pharmacokinet.*; 34(5): 359-373 (1998).
153. Ioannides-Demos LL, Liolios LL, Wood P, Spicer WJ, Mc Lean AJ. Changes in MIC alter responses of *Pseudomonas aeruginosa* to tobramycin exposure. *Antimicrob Agents Chemother.*; 42(6): 1365-1369 (1998).
154. Phillips JK, Mc Lean AJ, Hill CE Receptors involved in nerve-mediated vasoconstriction in small arteries of the rat hepatic mesentery. *Brit J Pharmacol* ;124: 1403-1412 (1998).
155. Le Couteur DG, Hickey H, Harvey PJ, Gready, J, Mc Lean AJ Hepatic artery flow and propranolol metabolism in the perfused cirrhotic rat liver. *J Pharmacol Exp Ther* 289:1553-1558 (1999).
156. Cholewka KA, Ioannides-Demos LL, Liolios LL, Paull P, Spicer WJ, Mc Lean AJ Cephalosporin clinical concentration-time profile modelling and in vitro bactericidal effects on *Escherichia coli*. *J. Antimicrob. Chemother.* 44: 471-476 (1999).

157. Le Couteur DG, Yin ZL, Rivory LP, McLean AJ. Carbon monoxide disposition in the perfused rat liver. *Am J Physiol* 277: G725-G730 (1999).
158. Le Couteur DG, McLean AJ, Blackburn AC, Mellick GD, Board PG. Glutathione transferase polymorphism and Parkinson's disease. *Lancet* 353: 71-72 (1999).
159. Le Couteur DG, Woodham b, Taylor M, McLean AJ, Board PG. Pesticides and Parkinson's disease. *Biomed & Pharmacother* 53: 122-30 (1999).
160. Fisher A, McLean AJ, Purcell P, Herdson P, Dahlstrom J, Le Couteur DG. Focal necrotising vasculitis with myositis following fluxetine administration. *Australian and New Zealand Journal of Medicine*. 29: 375-376 (1999).
161. Le Couteur DG, Hickey H, Harvey PJ, McLean AJ. Oxidative injury reproduces age-related change in oxygen dependent drug metabolism. *Pharmacology & Toxicology* 85:230-232 (1999).
162. McLean AJ, Le Couteur DG, Henizow BG. Hepatic artery flow change and hepatocyte oxygenation in human cirrhosis. *Gastroenterology* 117: 1257-9 (1999).
163. Harvey PJ, Le Couteur D, McLean AJ. Hepatic oxygen supplementation as therapy in cirrhotic liver disease. *Gastroenterology* 117:1025-6 (1999).
164. Le Couteur DG, McLean AJ. Ageing and reoxygenation injury in the liver. *Scand J Gastroenterol*. 34:735-736. (1999).
165. Harvey PJ, Gready JE, Hickey HM, Le Couteur DG, McLean AJ. ³¹P and ¹H NMR spectroscopic studies of liver extracts of carbon tetrachloride-treated rats. *NMR Biomed*. 12:395-401 (1999).
166. Davis MW, Le Couteur DG, Trim G, Buchanan J, Rubenach S, McLean AJ. Older people in hospital. *Australian Journal on Ageing* 18 (Suppl): 26-31, (1999).
167. Harvey PJ, Gready JE, Yin ZL, Le Couteur DG, McLean AJ. Acute oxygen supplementation restores markers of hepatocyte energy status and hypoxia in cirrhotic rats. *JPET* 293:641-645 (2000).
168. Yang MC, McLean AJ, Rivory LP, Le Couteur DG. Hepatic disposition of neurotoxins and pesticides. *Pharmacology & Toxicology* 87:286-291, (2000).
169. Le Couteur DG, Cogger VC, Markus VC, Harvey PJ, Yin ZL, Anselin AD, McLean AJ. Pseudocapillarisation and associated energy limitation in the aged rat liver. *Hepatology* 33: 537-543 (2001).

170. Cho CS, McLean AJ, Rivory LP, Gatenby PA, Hardman DT, Le Couteur DG. Carbon monoxide wash-in method to determine gas transfer in vascular beds: Application to rat hind limb. *American Journal of Physiology* 280: H1802-1806, (2001).
171. Cogger VC, Mross P, Hosie MJ, Ansellin AD, McLean AJ, Le Couteur DG. The effect of acute oxidative stress on the ultrastructure of the perfused rat liver. *Pharmacology & Toxicology* 89: 306-311, (2001).
172. Yang MC, McLean AJ, Le Couteur DG. Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPT.) in the liver and systemic bioavailability. *Biochem Bioph Res Com* 289:130-6, (2001).
173. Le Couteur DG, Muller M, Yang MC, Mellick GD, McLean AJ. Age-environment and gene-environment interactions in the pathogenesis of Parkinson' disease. *Rev Environ Health* 17:51-64 (2002).
174. Le Couteur DG, Fraser R, Cogger VC, McLean AJ. Hepatic pseudocapillarisation and atherosclerosis in ageing. *Lancet* 359:1612-1615, (2002).
175. Yang MC, McLean AJ, Le Couteur DG. Age-Related Alteration in Hepatic Disposition of the Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Pesticides. *Pharmacology & Toxicology* 90:203-7, (2002).
176. Harvey PJ, Gready JE, Yin Z, Le Couteur DG, McLean AJ. Hepatic phospholipid changes induced by sustained oxygen supplementation. *Pharmacol Toxicol* 91:150-2 (2002).
177. Fisher A, Croft-Baker J, Davis M, Purcell P, McLean AJ. Entacapone – induced hepatotoxicity and hepatic dysfunction. *Movement Disorders* 17:1362-5 (2002).
178. Croft-Baker JN, Croft-Baker LA, Le Couteur DG, McLean AJ. Age related factors determining safe prescribing for older people. *CME Geriatric Medicine* 4(1): 4-8 (2002).
179. McLean AJ, Purcell P, Entacapone hepatotoxicity and Managed versus Spontaneous Adverse Drug Reaction Reporting *Movement Disorders* 17: 1399-1400 (2002).
180. Fisher A, Davis M, Croft-Baker J, Purcell P, McLean AJ. Citalopram-Induced Severe Hyponatraemia with Coma and Seizure. Case report with literature and spontaneous reports review. *Adverse Drug React Toxicol Rev* 21:179-187 (2002).
181. Sangalli MR, McLean AJ, Peek MJ, Rivory LP, Le Couteur DG. Carbon monoxide disposition and permeability-surface area product in the fetal circulation of the perfused term human placenta. *Placenta* 24:8-11 (2003).
182. Le Couteur DG, Fisher AA, Davis MW, McLean AJ. Postprandial Systolic Blood Pressure Responses Of Older People In Residential Care - Association With Risk Of Falling. *Gerontol* 49:4 260-264 (2003).
183. McLean AJ. The future of aged care *Intern Medicine J.* 33(4):174-6 (2003)

184. McLean AJ, Cogger VC, Chong GC, Warren A, Markus AMA, Dahlstrom JE, Le Couteur DG. Age-Related Pseudocapillarization of The Human Liver. *J Pathol* 200:112-117. (2003)
185. Meaklim J, Yang J, Drummer OH, Killalea S, Staikos V, Horomidis S, Rutherford D, Ioannides-Demos LL, Lim S, McLean AJ, McNeil J. Fenitrothion: toxicokinetics and toxicologic evaluation in human volunteers. *Environ Health Perspect* 111: 305-8 (2003)
186. Fisher AA, McLean AJ, Davis MW, Le Couteur DG. A multi-center, case control study of the effects of antihypertensive therapy on orthostatic hypotension, postprandial hypotension and falls in octo- and nonagenarians in residential care facilities. *Current Therapeutic Research* 64 (3): 206-214, (2003)
187. Bassett ML, Dahlstrom JE, Taylor MC, Koina M, Maxwell L, Francis D, Jain S, McLean AJ. Ultrastructural changes in hepatic sinusoidal endothelial cells acutely exposed to colloidal iron. *Exp Toxicol Pathol.* 55 (1):11-6. (2003)
188. Cogger VC, Warren A, Fraser R, Ngu M, McLean AJ, Le Couteur DG. Hepatic sinusoidal pseudocapillarization with aging in the non-human primate. *Exp. Gerontol.* 38 (10), 1101-1107 (2003)
189. Hilmer SN, Warren A, Cogger VC, Fraser R, McLean AJ, Sullivan D, Le Couteur DG. The Effect Of Aging On The Immunohistochemistry Of Apolipoprotein E In The Liver. *Exp. Gerontol.* 39 (1), 53-7 (2004)
190. McLean AJ, Safe Blood Pressures in the elderly and use of antihypertensives. *The Royal Australian College of General Practitioners, GP Review, Vol 8 (3):12-13, (2004)*
191. McLean AJ, Le Couteur DG. Aging Biology and Geriatric Clinical Pharmacology. *Pharmacological Reviews* 56: 163-184 (2004)
192. Cogger VC, Warren A, Fraser R, Ngu M, McLean AJ, Le Couteur DG. Preliminary analysis of the sinusoidal endothelium and space of Disse in ageing Papio hamadryas. *Comp Hepatol.* 14; 3 Suppl 1:S26 (2004)
193. Cogger VC, Muller M, Fraser R, McLean AJ, Khan J, Le Couteur DG. The effects of oxidative stress on the liver sieve. *J Hepatol.* 41:370-6 (2004)
194. Kuchel PW, Bubb WA, Ramadan S, Chapman BE, Philp DJ, Coen M, Gready JE, Harvey PJ, McLean AJ, Hook J. ³¹P MAS-NMR of human erythrocytes: independence of cell volume from angular velocity. *Magn Reson Med.* 52:663-8. (2004)
195. Le Couteur DG, Yin ZL, McLean AJ, Rivory LP. Wash-in methodology and modelling to determine hepatocellular D-glucose transport in the perfused rat liver. *Jpn J Physiol.* 54: 421-9 (2004)
196. Graffen M, Saligari M, Le Couteur DG, Naganathan V, McLean AJ. Development of a mentorship programme for rural general practitioners by visiting specialist physicians. *Rural and Remote Health* 5: 374-377 (2005)

197. Warren A, Bertolino P, Cogger VC, McLean AJ, Fraser R, and LeCouteur DG. Hepatic pseudocapillarization in aged mice. *Exp Gerontol* 40: 807-12 (2005)
198. Fisher AA, Davis MW, McLean AJ, and Le Couteur DG. Epidemiology of falls in elderly semi-independent residents in residential care. *Australasian Journal on Ageing, Research*, 24; 98-102 (2005).
199. Hilmer SN, Warren A, Cogger VC, Fraser R, McLean AJ, Sullivan D, Le Couteur DG. Age-related changes in hepatic endothelium impede lipoprotein transfer in the Rat. *Hepatology* 42; 1349-1354 (2005)
200. Le Couteur DG, Fraser R, Hilmer H, Rivory LP, McLean AJ. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. *Clin Pharmacokinet* 44: 187-200 (2005)
201. McLean AJ, Allsop I. Consumer participation in Health and Medical Research – The perspective of the National Ageing Research Institute. *The Australian Health Consumer* 1; 12-14, 2005-2006,
202. Joubert J, Cumming TB, McLean AJ. Diversity of risk factors for stroke: the putative roles and mechanisms of depression and air pollution. *J Neurol Sciences* 262: 71-76, 2007
203. Joubert J, McLean AJ et al. Stroke prevention in small communities and rural settings. *Stroke* (in press) 2008



OTHER PUBLICATIONS

BOOKS,

Current Problems in Nutrition, Pharmacology and Toxicology, Ed. McLean, A.J. and Wahlqvist, M.L. J Libbey and Co. London, (1988).

Advances in Clinical Nutrition II, Eds AJ McLean and ML Wahlquist, Johns and Co. London and Paris, (1988)

BOOK CHAPTERS & MAJOR REPORTS

McNay JL, Haegele KD, McLean AJ. Duration of hydralazine action. Proceedings of the International Meeting on Pharmacological and Clinical Aspects of Apresoline. In: Today's Treatment of Hypertension, Oslo, Norway, April (1977)

Melander A, Lalka D and McLean AJ: Influence of food on the presystemic clearance of drugs. In International Encyclopedia of Pharmacology and Therapeutics, Gibaldi M. Ed. (1984)

Frew JL, McLean AJ. Report of Ministerial Working Party on Drug Use in Victorian Public Hospitals. Victorian Health Department. December (1984).

McLean AJ, Lalka D, Corcoran GB, Melander A. Drug nutrient interactions. In : Recent Advances in Clinical Nutrition, pp 1-7. Ed. Truswell, A.S. and Wahlqvist, M.L. J. Libbey and Co. London, (1986).

Ruffin RE & McLean AJ. Pulmonary pharmacology. In: Drug Use in Respiratory Disease, pp 1-10. Adis Press Australasia. Sydney, (1987).

McLean AJ. Change in lifestyle and diet versus drug use in non-insulin dependent Diabetes Mellitus (NIDDM). In: Current Problems in Nutrition, Pharmacology and Toxicology , pp 16-18. Ed. McLean, A.J. and Wahlqvist, M.L. J Libbey and Co., London, (1988).

Melander A, Lalka D, McLean AJ. Food and drug bioavailability. In: Current Problems in Nutrition, Pharmacology and Toxicology, pp 195-203. Ed. McLean, A.J. and Wahlqvist, M.L. J Libbey and Co. London, (1988).

Melander A, Lalka D and McLean A: Food and drug bioavailability, pp. 195 Advances in Clinical Nutrition II, Eds AJ McLean and W Wahlqvist, Johns and Co. London and Paris, (1988)

Ioannides-Demos LL & McLean AJ. The application of pharmacokinetics to practical drug dosing. In: Clinical Science for Surgeons: Basic Surgical Practice, 2nd edn. Ed Marshall, V and Ludbrook, J. Butterworths, North Ryde, N S W, (1988).

Lambert JR & McLean AJ. Pharmacology of colloidal bismuth subcitrate ("Denol") and use in non-ulcer dyspepsia. In: Helicobacter pylori in peptic ulceration and gastritis, pp 201-209. Ed Marshall BJ, McCallum RW & Guerrant RL. Blackwell Scientific Publications, Oxford, (1991).

Le Couteur DG, Khalil Z, Andrews G, Broe A, Darzins PJ, Flicker L, Kendig H, Kril J, McCallum J, McLean AJ, Nagley P, Nair K, Squires B, Yelland C. Scoping Study on Ageing Research Report, A National Consortium auspiced by the Centre for Education and Research on Ageing (CERA) and the National Ageing Research Institute (NARI). (2002).

Newell C, McKenzie A, Green A, Micklethwaite B, McLean AJ. A Model Framework for Consumer and Community Participation in Health and Medical Research, Investing in Australia's Health. National Health and Medical Research Council (2004)

Le Couteur DG, Naganathan V, Cogger VC, Cumming RG, McLean AJ. Pharmacotherapy in the Elderly: Clinical Issues and Perspectives. In Contemporary Perspectives on Clinical Pharmacotherapeutics. Editors: Kohil K, Gupta M, Tejwani S. (2006)

Le Couteur DG, VC Cogger, SN Hilmer, M Muller, M Harris, D Sullivan, AJ Mclean, R Fraser. Aging, Atherosclerosis And The Liver Sieve In Progress in Atherosclerosis Research Research . (Nova Science Publishers NY) (2006)